Related Experiment Video
Updated: Mar 29, 2026
Innovative Adipose Tissue Fractionation for Transforming Fat into Specialized Components
Published on: July 11, 2025
Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Results After Repeat Treatment
Leslie Baumann1, Rhoda S Narins, Kenneth Beer
1*Baumann Cosmetic and Research Institute, Miami, Florida; †Dermatology Surgery and Laser Center, New York, New York; ‡Beer Cosmetic, Surgical and General Dermatology, West Palm Beach and Jupiter, Florida; §The Westmount Institute of Plastic Surgery, Montreal, QC, Canada; ‖Cosmetic Laser Dermatology, San Diego, California; ¶Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, The Few Institute for Aesthetic Plastic Surgery, Chicago, Illinois; #Suffield, Connecticut; **Allergan plc, Irvine, California.
Repeat Juvéderm Voluma XC treatments effectively correct midface volume deficit with high patient satisfaction. This hyaluronic acid gel offers a safe and well-tolerated option for sustained facial rejuvenation.
Area of Science:
- Dermatology
- Aesthetic Medicine
- Plastic Surgery
Background:
- Juvéderm Voluma XC (VYC-20L), a hyaluronic acid gel, is FDA-approved for correcting age-related midface volume deficit.
- Understanding the outcomes of repeat treatments is crucial for long-term patient management.
Purpose of the Study:
- To evaluate the safety and effectiveness of repeat VYC-20L treatment for midface volume deficit.
- To assess patient-reported outcomes and satisfaction following repeat VYC-20L injections.
Main Methods:
- 167 subjects with midface volume deficit received optional repeat VYC-20L treatment 12-24 months post-initial treatment.
- Investigator and subject assessments included the Mid-Face Volume Deficit Scale (MFVDS) and Global Aesthetic Improvement Scale (GAIS).
- Subjective outcomes included satisfaction, goal achievement, and self-perception of age, with 30-day diaries for adverse events.
Main Results:
- Repeat treatment required approximately half the volume of initial treatments (3.13 mL vs. 6.8 mL).
- Effectiveness was confirmed across all investigator and subject-rated measures, mirroring initial treatment results.
- 82.8% and 91.1% of subjects showed improvement on the MFVDS at 6 and 12 months post-repeat treatment, respectively.
- Incidence, severity, and duration of treatment-site responses were reduced after repeat treatments.
Conclusions:
- Repeat VYC-20L treatment is well-tolerated, demonstrating sustained effectiveness and high subject satisfaction.
- The findings support VYC-20L as a safe and effective option for managing midface volume deficit over time.
